LT4801B - Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija - Google Patents

Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija Download PDF

Info

Publication number
LT4801B
LT4801B LT1999114A LT99114A LT4801B LT 4801 B LT4801 B LT 4801B LT 1999114 A LT1999114 A LT 1999114A LT 99114 A LT99114 A LT 99114A LT 4801 B LT4801 B LT 4801B
Authority
LT
Lithuania
Prior art keywords
apo
phytosterols
composition
disease
cholesterol
Prior art date
Application number
LT1999114A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99114A (lt
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of LT99114A publication Critical patent/LT99114A/xx
Publication of LT4801B publication Critical patent/LT4801B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT1999114A 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija LT4801B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor

Publications (2)

Publication Number Publication Date
LT99114A LT99114A (lt) 2001-01-25
LT4801B true LT4801B (lt) 2001-06-25

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
LT1999114A LT4801B (lt) 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija

Country Status (18)

Country Link
US (1) US5985936A (no)
EP (1) EP0967982A2 (no)
CN (1) CN1252724A (no)
AU (1) AU1656099A (no)
BG (1) BG103740A (no)
BR (1) BR9807577A (no)
CA (1) CA2281710A1 (no)
EE (1) EE9900354A (no)
GE (1) GEP20022783B (no)
HU (1) HUP0100737A3 (no)
LT (1) LT4801B (no)
LV (1) LV12438B (no)
MD (1) MD1920F2 (no)
NO (1) NO993979L (no)
PL (1) PL335421A1 (no)
RU (1) RU2173151C2 (no)
SK (1) SK112999A3 (no)
WO (1) WO1999032097A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
CN1436047A (zh) 2000-04-14 2003-08-13 马尔斯公司 促进血管健康的组合物和方法
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
JP2007526764A (ja) * 2004-01-22 2007-09-20 ジェネッサンス ファーマシューティカルズ，インコーポレイティド アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
EP1814575A4 (en) * 2004-11-24 2010-07-07 Neopro Labs Llc METHODS AND COMPOSITIONS FOR TREATING DISORDERS
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2012149111A1 (en) 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
RU2758376C2 (ru) 2017-09-14 2021-10-28 Феникс Байотекнолоджи, Инк. Способ и улучшенная нейропротекторная композиция для лечения неврологических патологических состояний
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US20230263809A1 (en) 2019-12-24 2023-08-24 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
BR9509119A (pt) * 1994-09-29 1997-10-28 Univ British Columbia Processo para o isolamento de uma composição de fitoesteróis a partir de um sabão de polpa composição diminuidora de colesterol e produto terapeuticamente eficaz para prevenir ou tratar aterosclerose ou dislipidemias primárias ou secundárias
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
ES2285772T3 (es) * 1997-05-15 2007-11-16 University Of Washington Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis.

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOYLES ET AL.: "A role for apoliprotein-E, apoliprotein A-I and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of tjr rat sciatic nerve", J. CLIN. INVEST., 1989, pages 1015 - 1031
ELSHOURBAGY ET AL.: "Apoliprotein E mRNA is abundant in the brain and adreals as well as in liver and is present in other peripheral tissues in rats and marmosets", PROC. NATI. ACAD. SCI. USA, 1985, pages 203 - 207
HANDELMANN ET AL.: "Effects of apolipoprotein E, Beta-very low density lipoproteins and cholesterol on the extension of neurits by rabit dorsal root ganglion neurons in vivo", J. LIPID RES., 1992, pages 1677 - 1688
MULLER M. ET AL.: "A specific 37.000-dalton protein that accumulates in regerating but non-regenerating mammalian", SCIENCE, 1985, pages 499 - 501
STRITTMATTER ET AL.: "Hypothesis: microtubule instability and paired helical filament formation in the Alzheimers desease brain are related to apolipoprotein-E genotype", EXP. NEUROL., 1994, pages 163 - 171
STRITTMATTER ET AL.: "Isoform specific interactions for Alzheimers desease", PROC NATL ACAD SCI U S A., 1994, pages 11183 - 11186

Also Published As

Publication number Publication date
PL335421A1 (en) 2000-04-25
MD1920F2 (ro) 2002-05-31
GEP20022783B (en) 2002-09-25
CA2281710A1 (en) 1999-07-01
LV12438A (en) 2000-03-20
US5985936A (en) 1999-11-16
WO1999032097A2 (en) 1999-07-01
LV12438B (en) 2000-09-20
RU2173151C2 (ru) 2001-09-10
EP0967982A2 (en) 2000-01-05
HUP0100737A3 (en) 2002-07-29
BG103740A (en) 2000-05-31
WO1999032097A3 (en) 1999-09-02
AU1656099A (en) 1999-07-12
MD990262A (en) 2000-06-30
NO993979L (no) 1999-10-13
SK112999A3 (en) 2001-11-06
BR9807577A (pt) 2001-08-07
EE9900354A (et) 2000-02-15
CN1252724A (zh) 2000-05-10
NO993979D0 (no) 1999-08-18
HUP0100737A2 (hu) 2001-09-28
LT99114A (lt) 2001-01-25

Similar Documents

Publication Publication Date Title
LT4801B (lt) Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija
Kariv-Inbal et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol
Chernick et al. Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier
Salem Jr et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Troutwine et al. Apolipoprotein E and Alzheimer's disease
Martins et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Leduc et al. APOE and cholesterol homeostasis in Alzheimer's disease
Vance et al. Cholesterol homeostasis in neurons and glial cells
Yu et al. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits
Karten et al. Mechanisms and consequences of impaired lipid trafficking in Niemann–Pick type C1-deficient mammalian cells
Stein et al. Lipid transfer proteins (LTP) and atherosclerosis
Maria Giudetti et al. The role of brain cholesterol and its oxidized products in Alzheimer's disease
Montine et al. Central nervous system lipoproteins in Alzheimer's disease.
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Turri et al. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Takechi et al. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
Berbée et al. Apolipoprotein CI knock-out mice display impaired memory functions
Dragan et al. Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?
EP2538951A1 (en) Agents and mechanisms for treating hypercholesterolemia
Levi et al. Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation
Blain et al. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease
Xu et al. Lipid metabolism in Alzheimer's and Parkinson's disease
Hone et al. Fat and lipid metabolism and the involvement of apolipoprotein E in Alzheimer's disease
MXPA99007622A (en) Method of preventing and delaying the onset of alzheimer's disease and composition therefor
JP2001512494A (ja) アルツハイマー病を予防するまたはその発病を遅延させる方法およびそのための組成物

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20021218